Therapeutic Drug Monitoring for Biologics in Inflammatory Bowel Disease
Originally presented May 8, 2024
Overview
Over the past 10 years, the therapeutic arsenal for inflammatory bowel disease has grown exponentially, from TNF inhibitors such as infliximab, to anti-integrins (e.g., vedolizumab) and anti-interleukins (e.g., ustekinumab, risankizumab) amongst other drug classes. Given that the monoclonal antibody therapies are generally immunogenic, there are several laboratory assays to monitor patients in reactive or proactive stages of response assessment.
This webinar will cover the laboratory tests available to monitor patients using monoclonal antibody therapies for treatment of inflammatory bowel disease. Focus will be shared between analytical approaches as well as literature and practice recommendations for tests results interpretation.
Presenters
Maria Alice Willrich, Ph.D.
Associate Professor of Laboratory Medicine and Pathology
Department of Laboratory Medicine and Pathology
Mayo Clinic
Rochester, Minnesota
Michelle D. Becker, Pharm.D., R.Ph., BCACP
Assistant Professor of Pharmacy
Division of Gastroenterology and Hepatology
Mayo Clinic
Rochester, Minnesota
Learning objectives
Upon completion of this activity, participants should be able to:
- Describe the analytical methods employed for the measurement of monoclonal antibody therapies concentration and anti-drug antibodies.
- Differentiate between reactive and proactive monitoring of monoclonal antibody therapies.
- Develop plan for therapeutic drug monitoring based on patient- and drug-specific considerations.
- Interpret therapeutic drug monitoring lab results to determine best next steps for a medical treatment plan.
Intended audience
This webinar is appropriate for any provider who sees patients with inflammatory bowel disease, gastroenterologists, primary care internal medicine, laboratory directors, lab supervisors, pathologists, pharmacists, and laboratory send-out coordinators/managers.
Questions
Contact us: mcleducation@mayo.edu
